Revolution Medicines, Inc. Payments of Debt Issuance Costs
Revolution Medicines, Inc. (RVMD) reported Payments of Debt Issuance Costs of $5.00 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Financing Activities
us-gaap:PaymentsOfDebtIssuanceCosts · last filed 2026-08-05
- Revolution Medicines, Inc. payments of debt issuance costs for the quarter ending 2026-06-30 was $5.00M.
- Revolution Medicines, Inc. payments of debt issuance costs for the quarter ending 2026-03-31 was $0.00.
- Revolution Medicines, Inc. payments of debt issuance costs for the quarter ending 2025-12-31 was $0.00.
- Revolution Medicines, Inc. payments of debt issuance costs for the quarter ending 2025-09-30 was $0.00.
- Revolution Medicines, Inc. payments of debt issuance costs for fiscal 2025 was $5.79M.
| Period end | Payments of Debt Issuance Costs 1 month | Payments of Debt Issuance Costs 1 month as first filed | Payments of Debt Issuance Costs 3 month | Payments of Debt Issuance Costs 6 month | Payments of Debt Issuance Costs 9 month | Payments of Debt Issuance Costs 12 month |
|---|---|---|---|---|---|---|
| 2026-06-30 | $5.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $5.00M 10-Q · filed 2026-08-05 | $5.00M derived: sum of 3 quarters · filed 2026-08-05 | $5.00M derived: sum of 4 quarters · filed 2026-08-05 | ||
| 2026-03-31 | $0.00 10-Q · filed 2026-05-06 | $0.00 derived: sum of 2 quarters · filed 2026-05-06 | $0.00 derived: sum of 3 quarters · filed 2026-05-06 | |||
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $0.00 derived: sum of 2 quarters · filed 2026-02-25 | $5.79M 10-K · filed 2026-02-25 | |||
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $5.79M 10-Q · filed 2025-11-05 | ||||
| 2025-06-30 | $10.80M 10-Q · filed 2026-08-05 | $5.80M 10-Q · filed 2026-05-06 | $5.79M 10-Q · filed 2025-08-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |